On November 14, 2024 Flamingo Therapeutics ("Flamingo") reported an oral presentation at the AACR (Free AACR Whitepaper) Special Conference in Cancer Research, RNAs as Drivers, Targets, and Therapeutics in Cancer, being held in Seattle, Washington from November 14-17, 2024 (Press release, Flamingo Therapeutics, NOV 14, 2024, View Source;utm_medium=rss&utm_campaign=flamingo-therapeutics-announces-oral-presentation-at-aacr-special-conference-in-cancer-research-on-rnas-as-drivers-targets-and-therapeutics-in-cancer [SID1234648397]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Andrew Denker, Flamingo’s Chief Medical Officer, will deliver an oral presentation on the Company’s approach to developing RNA therapeutics against difficult-to-drug targets for cancer indications. Dr. Denker will discuss Flamingo’s novel oligonucleotide targeting the long noncoding RNA (lncRNA) MALAT1, FLM-7523, discovered by Ionis Pharmaceuticals, which has recently completed IND-enabling preclinical activities and is moving toward a Phase 1 First-in-Human trial in solid tumors. Flamingo’s lead program, danvatirsen, is an antisense oligonucleotide discovered by Ionis that selectively targets STAT3 mRNA and has shown clinical activity in HNSCC.
"I am excited that Flamingo’s approach to leveraging RNA for cancer drug development will be showcased at this important scientific meeting," commented Dr. Denker. "Long noncoding RNAs, part of the genetic ‘dark matter’, are gaining attention as potential novel targets in cancer and other diseases. The antisense oligonucleotide therapeutic modality is uniquely suited for lncRNA targets, and FLM-7523 is one of the most advanced therapeutics in development. We look forward to highlighting our approach at the AACR (Free AACR Whitepaper) Special Conference."
Oral presentation details are as follows:
Title: "Antisense Oligonucleotides as Therapeutics for Difficult-to-Drug Targets in Oncology"
Session Title: Plenary Session 6: Small RNA Therapeutics
Session Date and Time: Saturday, November 16, 2024, 3:30 pm
Presenting Author: Dr. Andrew Denker
Abstracts selected for presentation during the meeting (poster or oral) will be published as a freely available supplement in an AACR (Free AACR Whitepaper) journal on the first day of the meeting. For more information, please visit the AACR (Free AACR Whitepaper) Special Conference 2024 website.